Characteristics of Patients Experiencing Complete Remission After Therapy With Anti-Idiotype Antibodies
| Patient . | Tumor Histology . | Stage . | Prior Therapy (Courses) . | Duration of Prior Remission (months) . | Treatment Regimens . | Dose (mg) . | Time Until Achievement of Best Response (months) . | DFS (years) . |
|---|---|---|---|---|---|---|---|---|
| 1 | FSC | IVB | IFN × 3 | 12 | Anti-id | 400 | 3 | 7* |
| CVP/B × 2 | XRT | |||||||
| 13 | FSC | IVB | Splenectomy | NA | Anti-id + IFN | 4,200 | 18 | 10+ |
| 14 | FSC | IVA | CVP × 2 | 4 | Anti-id + IFN | 8,030 | 8 | 9.5+ |
| Chl | ||||||||
| CVbP | ||||||||
| 17 | FM | IIIA | None | NA | Anti-id | 6,908 | 23 | 9.5+ |
| 24 | FSC | IVA | Chl × 2 | 4 | Anti-id + Chl | 3,840 | 17 | 2.5 |
| 34 | FSC | IVA | Chl | 4 | Anti-id + IL-2 | 7,792 | 3 | 4.5 |
| CVP | ||||||||
| 44 | F + DSC | IVA | CVP × 2 | 12 | Anti-id | 6,500 | 12 | 4.0+ |
| 45 | F + DM | IVA | CVP | 29 | Anti-id | 8,200 | 11 | 1.5 |
| Patient . | Tumor Histology . | Stage . | Prior Therapy (Courses) . | Duration of Prior Remission (months) . | Treatment Regimens . | Dose (mg) . | Time Until Achievement of Best Response (months) . | DFS (years) . |
|---|---|---|---|---|---|---|---|---|
| 1 | FSC | IVB | IFN × 3 | 12 | Anti-id | 400 | 3 | 7* |
| CVP/B × 2 | XRT | |||||||
| 13 | FSC | IVB | Splenectomy | NA | Anti-id + IFN | 4,200 | 18 | 10+ |
| 14 | FSC | IVA | CVP × 2 | 4 | Anti-id + IFN | 8,030 | 8 | 9.5+ |
| Chl | ||||||||
| CVbP | ||||||||
| 17 | FM | IIIA | None | NA | Anti-id | 6,908 | 23 | 9.5+ |
| 24 | FSC | IVA | Chl × 2 | 4 | Anti-id + Chl | 3,840 | 17 | 2.5 |
| 34 | FSC | IVA | Chl | 4 | Anti-id + IL-2 | 7,792 | 3 | 4.5 |
| CVP | ||||||||
| 44 | F + DSC | IVA | CVP × 2 | 12 | Anti-id | 6,500 | 12 | 4.0+ |
| 45 | F + DM | IVA | CVP | 29 | Anti-id | 8,200 | 11 | 1.5 |
The Disease Free Survival (DFS) is listed in the final column, with ongoing remissions printed in bold-faced type and notated with a + sign.
Abbreviations: Histologies: FSC, follicular small cleaved; FM, follicular mixed; F + DM, follicular and diffuse mixed; F + DSC, follicular and diffuse small cleaved; Therapies: IFN, alpha interferon; Chl, chlorambucil; C, cyclophosphamide; V, vincristine; Vb, vinblastine; P, prednisone; B, bleomycin; NA, these patients did not receive systemic therapy before trial entry.
Patient 1 received local XRT after a local relapse at 7 years and subsequently has been in continuous and ongoing remission for an additional 9 years.